MoonLake Immunotherapeutics
MLTX15.510USD
+0.740+5.01%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
988.06MCap. mercado
PérdidaP/E TTM
Más Datos de MoonLake Immunotherapeutics Compañía
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Información de MoonLake Immunotherapeutics
Símbolo de cotizaciónMLTX
Nombre de la empresaMoonLake Immunotherapeutics
Fecha de salida a bolsaOct 20, 2020
Director ejecutivoSantos Da Silva (Jorge)
Número de empleados100
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 20
DirecciónDorfstrasse 29
CiudadZUG
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísSwitzerland
Código postal6300
Teléfono41415108022
Sitio Webhttps://moonlaketx.com/
Símbolo de cotizaciónMLTX
Fecha de salida a bolsaOct 20, 2020
Director ejecutivoSantos Da Silva (Jorge)
Ejecutivos de MoonLake Immunotherapeutics
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.96M
-167519.00%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.28M
+354296.00%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.96M
-167519.00%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.28M
+354296.00%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 7 de feb
Actualizado: sáb., 7 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BVF Partners L.P.
27.88%
Deep Track Capital LP
6.51%
Santos da Silva (Jorge)
4.34%
Reich (Kristian)
4.18%
Avoro Capital Advisors LLC
2.82%
Otro
54.27%
Accionistas
Accionistas
Proporción
BVF Partners L.P.
27.88%
Deep Track Capital LP
6.51%
Santos da Silva (Jorge)
4.34%
Reich (Kristian)
4.18%
Avoro Capital Advisors LLC
2.82%
Otro
54.27%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
47.83%
Individual Investor
10.56%
Investment Advisor
6.71%
Investment Advisor/Hedge Fund
5.77%
Research Firm
1.10%
Venture Capital
0.49%
Sovereign Wealth Fund
0.33%
Bank and Trust
0.11%
Pension Fund
0.04%
Otro
27.06%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
347
43.70M
61.69%
-21.61M
2025Q3
336
52.26M
73.22%
-13.87M
2025Q2
326
71.15M
112.06%
-8.45M
2025Q1
329
71.47M
112.59%
-8.98M
2024Q4
308
74.57M
117.86%
+1.09M
2024Q3
292
73.42M
116.42%
+551.38K
2024Q2
282
72.21M
114.78%
+1.82M
2024Q1
274
70.82M
112.58%
-306.27K
2023Q4
260
64.82M
107.09%
-2.17M
2023Q3
219
60.33M
114.64%
-5.55M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BVF Partners L.P.
19.75M
27.88%
--
--
Nov 06, 2025
Deep Track Capital LP
4.61M
6.51%
+4.61M
--
Nov 05, 2025
Santos da Silva (Jorge)
3.07M
4.34%
-3.68K
-0.12%
Dec 19, 2025
Reich (Kristian)
2.96M
4.18%
-167.52K
-5.35%
Dec 19, 2025
Avoro Capital Advisors LLC
2.00M
2.82%
-2.15M
-51.81%
Sep 30, 2025
Cormorant Asset Management, LP
1.99M
2.81%
-6.50M
-76.52%
Sep 30, 2025
Balyasny Asset Management LP
1.70M
2.4%
+1.28M
+301.55%
Sep 30, 2025
Adage Capital Management, L.P.
1.50M
2.12%
+1.50M
--
Sep 30, 2025
Bodenstedt (Matthias)
922.01K
1.3%
+294.47K
+46.93%
Dec 19, 2025
Schonfeld Strategic Advisors LLC
965.40K
1.36%
+965.40K
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
ALPS Medical Breakthroughs ETF
0.27%
Global X Guru Index ETF
0.22%
Virtus LifeSci Biotech Clinical Trials ETF
0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.02%
Strive Small-Cap ETF
0.02%
Nuveen ESG Small-Cap ETF
0.02%
iShares Morningstar Small-Cap ETF
0.01%
John Hancock Multifactor Small Cap ETF
0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
Ver más
ALPS Medical Breakthroughs ETF
Proporción0.27%
Global X Guru Index ETF
Proporción0.22%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proporción0.02%
Strive Small-Cap ETF
Proporción0.02%
Nuveen ESG Small-Cap ETF
Proporción0.02%
iShares Morningstar Small-Cap ETF
Proporción0.01%
John Hancock Multifactor Small Cap ETF
Proporción0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
Proporción0.01%
Fidelity Nasdaq Composite Index ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
